Conclusion. In a southern, predominantly African American overweight population, our results demonstrate low discontinuation rates associated with BIC/FTC/TAF, with rash being the predominate cause. Overall, 4% discontinued BIC/FTC/TAF due to AEs compared with 1% as reported in the package insert. Vf values were high throughout the evaluation period. Ongoing post-marketing evaluation is important for early recognition of unexpected adverse outcomes.

Disclosures. All authors: No reported disclosures.

2490. Longer-Term Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed Adults Living With HIV and End-Stage Renal Disease on Chronic Hemodialysis

Joseph L. Eron, MD, MPH; Christopher D. Holodniy, MD; Robert Kalanyian, MD; Bhim Slim, MD; Anson K. Wurapa, MD; Jeffrey L. Stephens, MD; Cheryl McDonald, MD; Eric Cua, MD; Arjun Wilkin, MD, MPH; Mehr McKellar, MD; Stephanie Cox, BS; Sophia Schmidt, PharmD; Pham Thi Lien, MD; Christiana Blair, MS; Christoph C. Carter, MD; Devi SenGupta, MD; Diana M. Brainard, MD; Moupali Das, MD; University of North Carolina, Chapel Hill, Chapel Hill, North Carolina; Hôpital Henri Mondor, Créteil, Ile-de-France, France; Saint Michael's Medical Center, Newark, New Jersey; Infectious Disease Specialists of Atlanta, Atlanta, Georgia; Mercer University School of Medicine, Macon, Georgia; Tarrant County Infectious Disease Associates, Fort Worth, Texas; Nice University Hospital, Nice, Provence-Alpes-Cote d’Azur, France; Wake Forest University, Winston Salem, North Carolina; Duke University Hospital, Durham, North Carolina; Gilead Sciences Inc., Foster City, California; Gilead Sciences, Foster City, California

Session: 262. HIV: Antiretroviral Therapy
Saturday, October 5, 2019: 12:15 PM

Background. HIV treatment for individuals with end-stage renal disease (ESRD) on hemodialysis (HD) has previously required complex dose-adjusted regimens. We evaluated the safety and efficacy of single-tablet, once-daily elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide (E/C/F/TAF) in people living with HIV (PLH) on ESRD on chronic HD.

Methods. Virologically suppressed adult PLH with ESRD on chronic HD for ≥6 months were switched to open-label E/C/F/TAF 150/150/200/10 mg once daily for 96 weeks. Efficacy was assessed as the proportion of participants who maintained virologic suppression (HIV RNA < 50 copies/mL) using the snapshot algorithm. Safety and participant satisfaction were assessed throughout the study.

Results. We enrolled 55 participants with median age 51 years (range 23–64) with median HD years (range 1–17). In the per protocol analysis set, virologic suppression was maintained in 30 of 31 participants (96.8%, 95% CI [83.3%, 99.9%]) at week 96. In the full analysis set, virologic suppression was maintained in 30 of 55 participants (54.5%; 95% CI [40.6%, 68.0%]); one discontinued therapy due to lack of efficacy, and W96 data were unavailable for 24. Of the 24 participants lacking W96 data, 17 discontinued study drug early and 7 had missing data while on study drug; all had HIV RNA < 50 copies/mL at the last pre-week 96 check. Treatment-emergent AEs occurred in 53 (96.4%) participants, and study-drug-related AEs occurred in 7 (12.7%). Treatment-emergent AEs leading to premature study drug discontinuation occurred in 4 (7.3%) participants; two were considered study-drug-related (allergic pruritus and peripheral neuropathy in one participant each). No study-drug-related serious AEs were observed. 85.7% (30/35) of responding participants reported they were ‘much more satisfied’ with their regimen.

Conclusion. Single-tablet, once-daily E/C/F/TAF was effective in maintaining virologic suppression in PLH on chronic HD over 96 weeks of follow-up. E/C/F/TAF was well tolerated and was associated with improved participant satisfaction. These data demonstrate that E/C/F/TAF is a safe and effective alternative to more complicated regimens in PLH on chronic HD, with the potential to improve patient satisfaction and quality of life.

Disclosures. All authors: No reported disclosures.

2491. Virologic Response of Switching Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to Abacavir (ABC)-Based Regimen vs. Lopinavir/ Ritonavir (LPV/r) Plus Lamivudine (3TC) in HIV-Infected Patients with TDF-Induced Nephrotoxicity at 24 Weeks: A Prospective, Open-Label, Randomized, Controlled Trial

Nopporn Songumpai, MD; Oppas Putcharoen, MD, MSC; Division of Infectious Disease, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Krung Thep, Thailand; Division of Infectious Disease, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Krungthep, Krung Thep, Thailand

Session: 262. HIV: Antiretroviral Therapy
Saturday, October 5, 2019: 12:15 PM

Background. Tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity is a well-recognized complication and one of the reasons for treatment switching in HIV-infected patients. Several regimens in resource-poor settings such as abacavir (ABC)-based regimen or two-drug regimens such as boosted protease inhibitor (PI) plus lamivudine (3TC) are the options for switching. However, ABC is contraindicated in patients with a high risk for cardiovascular disease. Resource-limited setting, only some PIs such as lopinavir and atazanavir are available options.

Methods. We conducted a prospective, open-label, randomized controlled trial in a tertiary center in Bangkok. We recruited HIV-infected adults who had viral suppression, with TDF-induced proximal tubulopathy and/or a significant decrease in estimated glomerular filtration rate (eGFR). The patients were randomized to receive ABC/3TC plus efavirenz (ABC-based regimen) or LPV/r+3TC. The primary outcome was the proportion of patients with viral suppression at 24 weeks. The secondary outcomes were the immunologic response, recovery of GFR, proximal tubular function and change in lipid profile at 24 weeks.

Results. Between August 2018 - February 2019, we screened 87 patients and enrolled 24 patients were randomly assigned to the ABC-based regimen and 23 patients to LPV/r+3TC regimen. In the intention-to-treat population, virologic response at 24 weeks was noted in 21 (87.5%) patients assigned to ABC-based regimen and 19 (82.6%) patients assigned to LPV/r+3TC regimen (P = 0.635). There were no differences in the improvement of the percentage change of GFR, fractional excretion of phosphate, renal tubular reabsorption of phosphate (TmP/GFR), fractional excretion of uric and UPCR at 24 weeks. Triglyceride levels were significantly increased in LPV/r+3TC regimen compared with ABC-based regimen at 24 weeks (91.32% vs. 20.46%; P = 0.001).

Conclusion. Our study showed no difference in virologic suppression after switching to ABC-based regimen or LPV/r+3TC regimen in patients with TDF-induced nephrotoxicity. There was no difference in percentage change of GFR, recovering to INSTI-based regimen in both arms after discontinuation of TDF. There was a significant change in triglyceride levels in LPV/r+3TC regimen.

Disclosures. All authors: No reported disclosures.

2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-Based Therapy and Those Not Taking INSTIs in the Era of INSTI as Recommended First-line Therapy

Anne K. Monroe, MD, MPH; Matthew E. Levy, PhD; Alan E. Greenberg, MD, MPH; Richard Moore, MD, MHS; Jeanne Keruty, NP; Michael A. Horberg, MD; Bernade Mohanraj, MD; Princy Kumar, MD; Amanda Castel, MD, MPH; The George Washington University; Washington, DC; George Washington University Milton Institute School of Public Health, Washington, DC; The Johns Hopkins University School of Medicine, Baltimore, Maryland; Kaiser Permanente, Rockville, Maryland; Georgetown University School of Medicine, Washington, DC

Session: 262. HIV: Antiretroviral Therapy
Saturday, October 5, 2019: 12:15 PM

Background. Agents from the integrase inhibitor (INSTI) therapeutic class only are recommended as initial therapy for most patients with HIV. Clinicians now face a decision when treating ART-experienced patients on non-INSTI regimens: continue current therapy or switch to INSTI. Multiple factors may be considered in this decision: clinician/patient preference, comorbidities, tolerability, and resistance history. The objective of this analysis was to examine patient factors associated with currently taking INSTI-based regimens.

Methods. We used data from the DC Cohort, a longitudinal observational cohort of patients receiving HIV care at 14 clinics between 2011–2018. Participants in the sample had ≥1 encounter between 4/1/17 and 3/1/18, were aged ≥18 years and were ART experienced. Participants were classified as currently, previously, or never on an INSTI. Independent variables included demographics, clinical characteristics, alcohol/coffee use, HIV/HCV status and HIV-related variables (recent CD4 and HIV RNA, presence of resistance mutations). Multivariable multinomial logistic regression was used to identify factors associated with current INSTI use status.

Results. Among 4584 participants (58.2% aged ≥50 years; 69.4% male; 25% transgender; 80.3% Black; 36% MSM), most (65.0%) were current INSTI users; however, a sizeable proportion (28.3%) were never users and 6.7% were former users. Current INSTI users were more likely current users (aOR 1.90, 95% CI 1.18, 3.06), as were Hispanic participants (aOR 1.39, 95% CI 1.05, 1.84).

Conclusion. The majority of active DC Cohort participants were using INSTI-based therapy. Transgender and older individuals were less likely to be on INSTI, indicating that they are more likely to be on PI-based or NNRTI-based therapy or not on therapy. Further research should explore whether this is detrimental for long-term HIV resistance outcomes in these patient groups. Additionally, these results suggest resistance history as an important driver of INSTI prescription.

Table 1. Presence of Major Resistance Mutations among Individuals on ART in the DC Cohort, 2017–2018, n=4584

| Mutation | One year prior to current use | Two years prior to current use |
|----------|-----------------------------|--------------------------------|
| NRTI      | 45% (n=207)                 | 41% (n=202)                    |
| Major NRTI mutation | 0.001 | 0.001 |

Disclosures. All authors: No reported disclosures.